OptimizeRx's gross margin expanded from 62.0% in Q1 2024 to 76.5% in Q2 2026, and total debt fell from a $36.5M peak to $19.5M, which suggests the balance sheet and unit economics are strengthening.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | $0.16+44.0% vs $0.11 | $21M+1.5% vs $20M |
Q2 2026 May 12, 2026 | $0.14+1300.0% vs $0.01 | $20M+5.9% vs $19M |
Q2 2026 Mar 5, 2026 | $0.51+121.7% vs $0.23 | $32M+4.3% vs $31M |
Q4 2025 Nov 6, 2025 | $0.20+566.7% vs $0.03 | $26M-15.7% vs $31M |
WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, will hold a conference call on Wednesday, November 11, 2026, at 4:30 p.m.
Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).
Benchmark OPRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for OptimizeRx Corp. (OPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.76 | $164.38M | 35.77 | 18.78% | 4.66% | 3.6% | — | |
| $1.46 | $107.89M | -0.55 | 1.48% | -74.24% | -128.24% | — | |
| $32.51 | $6.08B | 43.70 | 13.05% | 21.12% | 14.81% | — | |
| $24.42 | $3.08B | 93.28 | 22.26% | 1.43% | 4.2% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $34.84 | $2.73B | 31.07 | 10.4% | 6.8% | 19.98% | — |
OptimizeRx Corp. (OPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
OptimizeRx Corp. (OPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 12, 2026·SEC
Jun 5, 2026·SEC
Get notified when OPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OptimizeRx Corp. (OPRX) stock FAQ — growth, dividends, profitability & financials explained
OptimizeRx Corp. (OPRX) reported $98.7M in revenue over the trailing twelve months. Revenue was $109.4M in fiscal year 2025. That is 108982% more than the $0.1M of fiscal year 2007.
OptimizeRx Corp. (OPRX) revenue fell by 5.8% over the trailing twelve months, compared with the twelve months before.
Yes. OptimizeRx Corp. (OPRX) earned $4.6M in net income over the trailing twelve months (a 4.7% net margin).
OptimizeRx Corp. (OPRX) had a return on equity (ROE) of 3.6% over the trailing twelve months. That is below the market's typical 10-15%.
OptimizeRx Corp. (OPRX) generated $18.4M in free cash flow over the trailing twelve months.
